导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.33% | 1667/2676 |
| 近一周 | -1.82% | 1587/3004 |
| 近一月 | - | 374/2984 |
| 近一季 | 1.45% | 424/2896 |
| 近半年 | -2.98% | 1325/2746 |
| 近一年 | 1.56% | 1344/2519 |
| 近两年 | 25.73% | 1484/1796 |
| 近三年 | 19.90% | 855/1340 |
| 成立以来 | 94.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.74% 2892/4961 |
-4.47% 3514/5312 |
- - |
- - |
| 2025 | 10.98% 2772/4813 |
-0.92% 2463/3635 |
2.55% 1495/4076 |
5.03% 3619/4524 |
3.98% 591/4813 |
| 2024 | 18.13% 624/3463 |
6.25% 305/2808 |
2.36% 354/3014 |
12.92% 2272/3129 |
-3.81% 2389/3463 |
| 2023 | -2.00% 550/2656 |
2.86% 1292/2280 |
-0.32% 376/2385 |
1.30% 317/2515 |
-5.64% 1435/2655 |
| 2022 | -9.73% 183/2207 |
-6.55% 219/1919 |
1.99% 1388/2016 |
-9.14% 248/2113 |
4.23% 573/2208 |
| 2021 | 2.08% 637/1822 |
1.41% 256/1255 |
-0.24% 1133/1330 |
-0.61% 498/1466 |
1.52% 890/1822 |
| 2020 | 20.28% 722/1250 |
-11.06% 813/1028 |
5.56% 878/1067 |
15.40% 216/1164 |
11.03% 567/1184 |
| 2019 | 24.98% 609/1092 |
20.46% 608/754 |
0.61% 166/804 |
-2.21% 690/850 |
5.44% 718/918 |
| 2018 | -18.24% 140/834 |
- - |
- - |
- - |
-11.36% 284/691 |
| 2017 | 21.52% 166/714 |
- - |
- - |
- - |
- - |
| 2016 | -5.78% 184/605 |
- - |
- - |
- - |
- - |
| 2015 | -2.36% 267/575 |
- - |
- - |
- - |
- - |
| 2014 | 65.09% 21/237 |
- - |
- - |
- - |
- - |
| 2013 | -7.58% 126/186 |
- - |
- - |
- - |
- - |
| 2012 | 13.58% 20/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.74% 24/102 |
- - |
- - |
- - |
- - |
| 2010 | -16.95% 42/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 交银上证180公司治理联接 VS. 长安沪深300非周期A(740101) |